SG11201906958TA - Aryl hydrocarbon receptor (ahr) modulator compounds - Google Patents
Aryl hydrocarbon receptor (ahr) modulator compoundsInfo
- Publication number
- SG11201906958TA SG11201906958TA SG11201906958TA SG11201906958TA SG11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ahr
- compounds
- aryl hydrocarbon
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17000158 | 2017-02-01 | ||
PCT/EP2018/052542 WO2018141857A1 (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906958TA true SG11201906958TA (en) | 2019-08-27 |
Family
ID=57960223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906958TA SG11201906958TA (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Country Status (28)
Country | Link |
---|---|
US (1) | US10981908B2 (uk) |
EP (1) | EP3577112B1 (uk) |
JP (1) | JP6849823B2 (uk) |
KR (1) | KR102320516B1 (uk) |
CN (1) | CN110248940B (uk) |
AR (1) | AR110789A1 (uk) |
AU (1) | AU2018216957B2 (uk) |
BR (1) | BR112019015716A2 (uk) |
CA (1) | CA3050827C (uk) |
CL (1) | CL2019002108A1 (uk) |
CO (1) | CO2019007881A2 (uk) |
CR (1) | CR20190392A (uk) |
CU (1) | CU20190069A7 (uk) |
EA (1) | EA038318B1 (uk) |
EC (1) | ECSP19055169A (uk) |
ES (1) | ES2858329T3 (uk) |
IL (1) | IL268080B (uk) |
MX (1) | MX2019008994A (uk) |
MY (1) | MY196831A (uk) |
NI (1) | NI201900076A (uk) |
PE (1) | PE20191478A1 (uk) |
PH (1) | PH12019550135A1 (uk) |
SG (1) | SG11201906958TA (uk) |
TW (1) | TWI752155B (uk) |
UA (1) | UA122745C2 (uk) |
UY (1) | UY37589A (uk) |
WO (1) | WO2018141857A1 (uk) |
ZA (1) | ZA201904771B (uk) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ,インコーポレイティド | AhRモジュレータ |
WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
AU2019387491A1 (en) * | 2018-11-30 | 2021-05-27 | Celularity Inc. | Expansion of natural killer cells and ILC3 cells with novel aromatic compounds |
EP4093739A1 (en) * | 2020-01-23 | 2022-11-30 | Phenex Pharmaceuticals AG | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
AU2021226411A1 (en) | 2020-02-26 | 2022-09-22 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of AhR signalling |
WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
CN115572282A (zh) * | 2021-07-05 | 2023-01-06 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8225991A (en) | 1990-07-31 | 1992-03-02 | Teikoku Hormone Mfg. Co., Ltd. | 2-phenylindole derivative |
IL129928A0 (en) * | 1996-11-19 | 2000-02-29 | Amgen Inc | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
WO2007057329A1 (en) | 2005-11-18 | 2007-05-24 | F. Hoffmann-La Roche Ag | Azaindole-2-carboxamide derivatives |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
US8604067B2 (en) | 2009-11-02 | 2013-12-10 | Ahr Pharmaceuticals, Inc. | ITE for cancer intervention and eradication |
ES2445917T3 (es) | 2010-02-03 | 2014-03-06 | Takeda Pharmaceutical Company Limited | Inhibidores de quinasa 1 reguladora de la señal de apoptosis |
US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
EP2909172A1 (en) | 2012-10-17 | 2015-08-26 | F. Hoffmann-La Roche AG | 6-aminoindole derivatives as trp channel antagonists |
SG10201707095QA (en) | 2012-12-21 | 2017-09-28 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-26 TW TW107102803A patent/TWI752155B/zh active
- 2018-01-31 UY UY0001037589A patent/UY37589A/es not_active Application Discontinuation
- 2018-01-31 AR ARP180100227A patent/AR110789A1/es unknown
- 2018-02-01 UA UAA201908353A patent/UA122745C2/uk unknown
- 2018-02-01 EP EP18701774.4A patent/EP3577112B1/en active Active
- 2018-02-01 EA EA201991599A patent/EA038318B1/ru unknown
- 2018-02-01 US US16/479,130 patent/US10981908B2/en active Active
- 2018-02-01 CR CR20190392A patent/CR20190392A/es unknown
- 2018-02-01 MY MYPI2019004031A patent/MY196831A/en unknown
- 2018-02-01 BR BR112019015716-6A patent/BR112019015716A2/pt not_active IP Right Cessation
- 2018-02-01 AU AU2018216957A patent/AU2018216957B2/en active Active
- 2018-02-01 MX MX2019008994A patent/MX2019008994A/es unknown
- 2018-02-01 SG SG11201906958TA patent/SG11201906958TA/en unknown
- 2018-02-01 CA CA3050827A patent/CA3050827C/en active Active
- 2018-02-01 JP JP2019561370A patent/JP6849823B2/ja active Active
- 2018-02-01 ES ES18701774T patent/ES2858329T3/es active Active
- 2018-02-01 KR KR1020197023990A patent/KR102320516B1/ko active IP Right Grant
- 2018-02-01 CU CU2019000069A patent/CU20190069A7/es unknown
- 2018-02-01 CN CN201880009354.9A patent/CN110248940B/zh active Active
- 2018-02-01 WO PCT/EP2018/052542 patent/WO2018141857A1/en unknown
- 2018-02-01 PE PE2019001482A patent/PE20191478A1/es unknown
-
2019
- 2019-07-15 NI NI201900076A patent/NI201900076A/es unknown
- 2019-07-15 IL IL268080A patent/IL268080B/en unknown
- 2019-07-19 ZA ZA2019/04771A patent/ZA201904771B/en unknown
- 2019-07-23 CO CONC2019/0007881A patent/CO2019007881A2/es unknown
- 2019-07-24 PH PH12019550135A patent/PH12019550135A1/en unknown
- 2019-07-29 CL CL2019002108A patent/CL2019002108A1/es unknown
- 2019-07-31 EC ECSENADI201955169A patent/ECSP19055169A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201408261UA (en) | Syringe | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201407200TA (en) | Liquid formulation | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201908513RA (en) | Peptides for treatment of diabetes | |
SG11201806424TA (en) | Therapeutic compounds |